Intra-Cellular Therapies (ITCI) News Today → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free ITCI Stock Alerts $67.97 -0.44 (-0.64%) (As of 09:52 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 8:00 AM | globenewswire.comIntra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare ConferenceJune 9 at 8:09 AM | marketbeat.comSchroder Investment Management Group Acquires 209,331 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Schroder Investment Management Group increased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 36.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 779,823 shares ofJune 8 at 4:28 PM | marketbeat.comSectoral Asset Management Inc. Has $531,000 Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Sectoral Asset Management Inc. cut its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 94.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,420 shares of the biopharmaceutical company's stock after selling 116,June 6, 2024 | marketbeat.com72,648 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Bought by TD Asset Management IncTD Asset Management Inc acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 72,648 shares of the biopharmaceutical company's stock, valued atJune 3, 2024 | marketbeat.comUBS Group AG Raises Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)UBS Group AG grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 205.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 134,762 shares of the biopharmaceutical company'June 3, 2024 | americanbankingnews.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Average Rating of "Moderate Buy" from AnalystsJune 3, 2024 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Average Recommendation of "Moderate Buy" from BrokeragesIntra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and nine have gJune 1, 2024 | marketbeat.comEagle Asset Management Inc. Has $31.21 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Eagle Asset Management Inc. boosted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 5.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 435,718 shares of the biopharmaceutical companyMay 30, 2024 | investorplace.comThe Secret Stock Stash: 3 Overlooked Picks That Belong in Every PortfolioMay 29, 2024 | ca.finance.yahoo.comITCI Aug 2024 65.000 putMay 29, 2024 | globenewswire.comIntra-Cellular Therapies to Present at the Jefferies Global Healthcare ConferenceMay 26, 2024 | marketbeat.comNorges Bank Buys New Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Norges Bank purchased a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,197,203 shares of the biopharmaceutical company's stock, valued at approximately $85,744,000. NorgesMay 23, 2024 | globenewswire.comIntra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual MeetingMay 22, 2024 | marketbeat.comClearbridge Investments LLC Increases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Clearbridge Investments LLC lifted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 10.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,553,135 shares of the biopharmaceutical company's stocMay 21, 2024 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Trading Up 3.7%Intra-Cellular Therapies (NASDAQ:ITCI) Stock Price Up 3.7%May 20, 2024 | marketbeat.comGW&K Investment Management LLC Has $116.62 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)GW&K Investment Management LLC decreased its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 3.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,628,244 shares of the biopharmaceutical company's stock after sellingMay 18, 2024 | marketbeat.comPrincipal Financial Group Inc. Boosts Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Principal Financial Group Inc. raised its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 10.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 460,566 shares of the biopharmaceuticaMay 15, 2024 | marketbeat.comNicholas Investment Partners LP Trims Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Nicholas Investment Partners LP reduced its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 85.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 50,244 shares of the biophaMay 12, 2024 | marketbeat.comSwiss National Bank Sells 19,400 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Swiss National Bank trimmed its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 10.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 170,400 shares of the biopharmaceutical cMay 10, 2024 | markets.businessinsider.comMaintained Buy Rating on ITCI Shares Amidst Strong Caplyta Revenue and Positive MDD Study OutlookMay 10, 2024 | marketbeat.comQ2 2024 EPS Estimates for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Boosted by Leerink PartnrsIntra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) - Equities research analysts at Leerink Partnrs boosted their Q2 2024 EPS estimates for shares of Intra-Cellular Therapies in a research report issued to clients and investors on Tuesday, May 7th. Leerink Partnrs analyst M. Goodman now exMay 9, 2024 | marketbeat.comAnalysts Issue Forecasts for Intra-Cellular Therapies, Inc.'s FY2025 Earnings (NASDAQ:ITCI)Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2025 earnings per share estimates for Intra-Cellular Therapies in a research note issued on Tuesday, May 7th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceuticaMay 8, 2024 | finance.yahoo.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Releases Earnings Results, Beats Expectations By $0.15 EPSIntra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The company had revenue of $144.90 million for the quarter, compared to the consensus estimate of $141.41 million. During the same period in the previous year, the firm earned ($0.46) EPS. Intra-Cellular Therapies's revenue was up 52.0% on a year-over-year basis.May 8, 2024 | finance.yahoo.comIntra-Cellular Therapies Inc (ITCI) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...May 7, 2024 | finanznachrichten.deIntra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Intra-Cellular Therapies Exceeds Q1 Expectations with Caplyta Sales SurgeMay 7, 2024 | msn.comITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comIntra-Cellular Therapies Surpasses Q1 Revenue Estimates with Strong CAPLYTA SalesMay 7, 2024 | marketbeat.comIntra-Cellular Therapies' (ITCI) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $90.00 target price on shares of Intra-Cellular Therapies in a research note on Tuesday.May 7, 2024 | msn.comIntra-Cellular Therapies beats Q1 estimatesMay 7, 2024 | globenewswire.comIntra-Cellular Therapies Reports First Quarter 2024 Financial ResultsMay 6, 2024 | marketbeat.comLisanti Capital Growth LLC Invests $3.79 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Lisanti Capital Growth LLC purchased a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 52,885 shares of the biopharmaceutical company'sMay 2, 2024 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by California Public Employees Retirement SystemCalifornia Public Employees Retirement System lifted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 14.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 160,376 sharesMay 1, 2024 | marketbeat.comIntra-Cellular Therapies (ITCI) to Release Quarterly Earnings on TuesdayIntra-Cellular Therapies (NASDAQ:ITCI) will be releasing earnings before the market opens on Tuesday, May 7, Zacks reports.April 30, 2024 | globenewswire.comIntra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and WebcastApril 29, 2024 | marketbeat.comPFG Investments LLC Purchases 11,000 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)PFG Investments LLC raised its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 392.9% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,800 shares of the biopharmaceuticalApril 26, 2024 | marketbeat.comEquities Analysts Set Expectations for Intra-Cellular Therapies, Inc.'s FY2024 Earnings (NASDAQ:ITCI)Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Intra-Cellular Therapies in a research note issued on Wednesday, April 24th. Cantor Fitzgerald analyst C. Duncan now forecasts that theApril 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)April 24, 2024 | finance.yahoo.comIntra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesApril 24, 2024 | globenewswire.comIntra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesApril 24, 2024 | marketbeat.comIntra-Cellular Therapies' (ITCI) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and set a $120.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday.April 24, 2024 | investorplace.com3 Biotech Stocks With Skyrocketing Potential: April 2024April 23, 2024 | marketbeat.comCanaccord Genuity Group Boosts Intra-Cellular Therapies (NASDAQ:ITCI) Price Target to $107.00Canaccord Genuity Group boosted their price target on Intra-Cellular Therapies from $100.00 to $107.00 and gave the stock a "buy" rating in a research report on Tuesday.April 22, 2024 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Price Target Raised to $90.00Needham & Company LLC boosted their price objective on shares of Intra-Cellular Therapies from $82.00 to $90.00 and gave the company a "buy" rating in a research report on Monday.April 22, 2024 | msn.comIpsen, Skyhawk enter RNA targeting research collab in rare neurological diseasesApril 21, 2024 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Holdings Increased by Knights of Columbus Asset Advisors LLCKnights of Columbus Asset Advisors LLC boosted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 100.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 54,499 shares of the biopApril 20, 2024 | money.usnews.comIntra-Cellular Therapies IncApril 17, 2024 | globenewswire.comIntra-Cellular Therapies Prices Public Offering of Common StockApril 17, 2024 | marketbeat.comThe Goldman Sachs Group Boosts Intra-Cellular Therapies (NASDAQ:ITCI) Price Target to $77.00The Goldman Sachs Group boosted their price target on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a "neutral" rating in a report on Wednesday. Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address It's time to ween off Chinese lithium! (Ad)As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely Learn how this American company is leading the lithium-ion revolution ITCI Media Mentions By Week ITCI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITCI News Sentiment▼1.360.76▲Average Medical News Sentiment ITCI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITCI Articles This Week▼44▲ITCI Articles Average Week Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KURA News IRWD News ZNTL News ZYME News CYRX News IGMS News PRLD News TEVA News ALNY News GMAB News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITCI) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored